Clinical

Using Mendelian randomization analysis, researchers found evidence that 2 small groups of immunophenotypes are linked to either greater or lesser odds of developing pulmonary arterial hypertension (PAH).

Despite advancements in umbilical cord blood transplants, social determinants of health, such as poverty and public insurance, continue to impact outcomes, underscoring the need for equitable access to lifesaving treatments.

Two posters presented at the CHEST 2024 annual meeting highlighted significant disparities in acute coronary syndrome care and outcomes among different racial, ethnic, and gender groups, underscoring the urgent need for targeted interventions to address these inequities.

Because sickle cell disease isn’t as progressive a disease as others that have gene therapies available, there isn’t as much urgency to start on these expensive therapies, said Kevin Niehoff, PharmD, BCMAS, associate director, Market and Financial Insights, IPD Analytics.

Two posters compared health care resource utilization (HCRU) and financial burdens of people living with HIV with a non-HIV population and people with HIV who are heavily treated with those have experienced less treatment.

Patients with low-count chronic lymphocytic leukemia phenotype monoclonal B-cell lymphocytosis had a 1.86-fold greater risk of melanoma.

Panelists discuss how health care providers can improve patient education and support for type 2 inflammatory conditions through personalized communication strategies and shared decision-making, while also evaluating the role of emerging biologic therapies in treatment plans based on individual patient factors, disease severity, and biomarker profiles.

The phase 2 PICCOLO trial demonstrated that mirvetuximab soravtansine (Elahere; AbbVie) is effective and tolerable in heavily pre-treated patients with folate receptor alpha-positive (FRα+), platinum-sensitive ovarian cancer.

Two posters at the CHEST 2024 annual meeting revealed that 18% of eligible patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) participated in post-discharge pulmonary rehabilitation (PR), with ineligibility significantly limiting uptake.

One of the key highlights was the discussion of Pulmonary Embolism Response Teams (PERT), addressing controversies in PE management and focusing on personalized, patient-centered care.

Two posters presented at CHEST 2024 revealed significant racial and ethnic disparities in the hospitalization and treatment of patients with idiopathic pulmonary fibrosis (IPF), with Black patients hospitalized at younger ages but less likely to receive antifibrotic medications than White patients.

Investigators added more data to an analysis first published in 2020 and got the same result: ruxolitinib beats other treatments for polycythemia vera.

Posters presented at the CHEST 2024 annual meeting demonstrated air pollution's role in lung impairment and disease, highlighting the urgent need for providers to address the escalating impacts of climate change on lung health.

Panelists discuss how incorporating HER2-directed therapies into NSCLC management strategies within managed care settings impacts clinical outcomes, operational processes, and economic considerations, while emphasizing the importance of identifying and selecting patient populations most likely to benefit from these targeted treatments.

A panel of experts explores the objectives and design of the COORDINATE-Diabetes trial, discussing its potential impact on the treatment paradigm for diabetes management.

Panelists discuss how persistent unmet needs in HER2-directed therapy for NSCLC present opportunities for future research and pipeline therapies, potentially addressing challenges such as treatment resistance, improved efficacy, or reduced toxicity profiles.

A panel of cardiometabolic risk management experts analyzes key takeaways from the UH CINEMA Program.

Ticiana Leal, MD, Winship Cancer Institutes, explains the importance of biomarker testing and multidisciplinary conversations while caring for patients with early-stage non–small cell lung cancer (NSCLC).

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.

The study is among the first to look at the potential impacts of clonal dynamics on patients with lower-risk myelodysplastic syndromes (MDS).

An August 2024 update to the National Comprehensive Cancer Network (NCCN) clinical practice guidelines for treatment of myeloproliferative neoplasms (MPN) calls puts a priority on clinical trials, even preferring them to FDA-approved therapies in some cases. Aaron Gerds, MD, MS, of Cleveland Clinic Taussig Cancer Institute discusses the updates and what's in the pipeline for MPN treatment.

Two posters highlighted the effects of sacubitril/valsartan (Entresto; Novartis) on key biomarkers and cardiac function in patients with heart failure with reduced ejection fraction (HFrEF), while also addressing prescription barriers for providers.

Study results show that a portable breath analysis device designed for early detection of non–small cell lung cancer may distinguish between patients with the disease and healthy individuals.